Skip to main content
Signal8

Anderman Jonathan

SEC insider (Form 3/4/5 filer). CIK 0002032625. General Counsel at Compass Therapeutics, Inc. (CMPX). 5 reported Form 4/5 transactions since Sep 2024; latest on Apr 29, 2026. Located in BOSTON, MA.

Companies Anderman Jonathan has filed insider reports for

  • Compass Therapeutics, Inc. (CMPX): Officer, General Counsel
Anderman Jonathan profile photo

Anderman Jonathan

CIK: 0002032625

Transaction Breakdown

Open Market Buys (P)2 (40.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (60.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

Compass Therapeutics, Inc. logo
CMPX

Compass Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (5 total)

  • Compass Therapeutics, Inc. logo
    CMPX

    Compass Therapeutics, Inc.

    Apr 29, 2026
    Purchase
    Direct
    25K shares at avg. $1.89$47K
  • Compass Therapeutics, Inc. logo
    CMPX

    Compass Therapeutics, Inc.

    Apr 29, 2026
    Award
    Direct
    25K shares at avg. $1.89$47K
  • Compass Therapeutics, Inc. logo
    CMPX

    Compass Therapeutics, Inc.

    Jan 2, 2026
    Award
    Direct
    150K shares at avg. $5.17$776K
  • Compass Therapeutics, Inc. logo
    CMPX

    Compass Therapeutics, Inc.

    Apr 7, 2025
    Purchase
    Direct
    20K shares at avg. $1.54$31K
  • Compass Therapeutics, Inc. logo
    CMPX

    Compass Therapeutics, Inc.

    Feb 11, 2025
    Award

    Stock Option (Right to Buy)

    Direct
    280K shares-

1-5 of 5